Takashi Takenoshita

Current Organisation: LRG1 LTD
(some projects in the list below may not be associated with this organisation)

Start Date

End Date Funded Value Relevance

CSV

25 50 100

£679,484

Apr 24 - Apr 25

Indication selection, patient stratification, and IND preparation for STX-002: the first-in-class LRG1 inhibitor for treatment of chronic kidney disease and immunotherapy-resistant tumours.

Innovate UK award to LRG1 LTD and Takashi Takenoshita

{{facetGroup.name}}

{{getFilterText(facet,showCount)}}